Dyne Therapeutics, Inc. $DYN Stock Holdings Increased by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 16.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,153,082 shares of the company’s stock after acquiring an additional 434,977 shares during the quarter. Dyne Therapeutics comprises 1.7% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 16th largest holding. Frazier Life Sciences Management L.P.’s holdings in Dyne Therapeutics were worth $61,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $51,000. Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after purchasing an additional 1,440 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Dyne Therapeutics by 1,006.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,499 shares of the company’s stock worth $205,000 after purchasing an additional 9,550 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the transaction, the director owned 11,663 shares in the company, valued at $229,527.84. This trade represents a 96.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by company insiders.

Dyne Therapeutics Trading Up 1.3%

Shares of DYN stock opened at $18.19 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $18.27 and its two-hundred day moving average is $18.18. The company has a market cap of $3.01 billion, a PE ratio of -5.65 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) EPS. Equities analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Wall Street Analysts Forecast Growth

DYN has been the subject of a number of research analyst reports. Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Chardan Capital reissued a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $35.00.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.